Y-mabs provides regulatory update on omburtamab for the treatment of patients with neuroblastoma

New york, june 23, 2021 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has recently concluded a type b meeting with the u.s. food and drug administration (“fda”) regarding omburtamab for the treatment of pediatric patients with cns/leptomeningeal metastasis from neuroblastoma.
YMAB Ratings Summary
YMAB Quant Ranking